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Objective: Benzodiazepines can be a problem if used for long periods, or in at-risk populations, such
as the elderly. We compared the use of benzodiazepine and related prescription medicines in Nova
Scotia and Australia.
Methods: The Nova Scotia Pharmacare Program and the Pharmaceutical Benefits Scheme in Australia
were used to obtain dispensing data in comparable populations for all publicly subsidized
benzodiazepines and related compounds. Usage was compared from 2000 to 2003, using the World
Health Organization anatomical therapeutic chemical and defined daily dosage (DDD) system. We also
determined differences in the types of benzodiazepines prescribed.
Results: The use of benzodiazepines increased at a steady but comparable rate in both areas. However,
the use of benzodiazepines in Nova Scotia was more than double that of Australia in 2000 (123 and
48 DDD/1000 beneficiaries per day, respectively) through 2003 (138 and 57 DDD/1000 beneficiaries
per day, respectively). Eight different benzodiazepines made up 90% of the drug use in Nova Scotia by
contrast to only 4 different benzodiazepines in Australia.
Conclusions: Large differences exist between the type and rate of benzodiazepine prescribing in Nova
Scotia and Australia, with Nova Scotia reporting more than twice as much use. Benzodiazepine use in
both jurisdictions is increasing. The Canadian findings are especially concerning as benzodiazepine use
in the Atlantic provinces has been reported to be less than other provinces. The variations between the
2 jurisdictions may be due to factors such as fewer benzodiazepines available in Australia, differences
in prescriber, patient attitudes and behaviours, or different initiatives to influence benzodiazepine use.
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Clinical Implications
 Benzodiazepine use differed markedly between Nova Scotia and Australia, with use being more than twice
as high in Nova Scotia.
 Increased use of benzodiazepines in Nova Scotia could be due to public subsidy of a wide range of these
compounds, or other factors such as organizational influences and culture.
 Our findings show the need for greater awareness of the level and burden of benzodiazepine use in those
aged 65 years and older, and the use of guidelines to improve prescribing.
Limitations
 Benzodiazepine comparative usage data were only for subsidized medicines, dispensed to individuals aged
65 years and older, and those who receive social security benefits.
 Only one Canadian province, Nova Scotia, was compared with Australia, as pharmaceutical subsidy is a
provincial responsibility in Canada.
 Dispensing data are not linked to clinical outcomes, therefore it was difficult to determine any clinical
reasons for higher use.
The long-term use of benzodiazepines is concerningbecause of the risk of dependence, cognitive impairment,
and falls and fractures.1–4 Patients aged 65 years and older
are particularly susceptible to the side effects of
benzodiazepines.5,6 For instance, the use of benzodiazepines
increases the risk of hip fracture in older individuals by at least
50%.5 Given the high morbidity and mortality of many of
these side effects, the benefits of benzodiazepines for older
individuals are unclear, especially as one-third of long-term
users do not display psychiatric symptoms requiring
benzodiazepines.7
There have been explicit guidelines on the inappropriateness
of benzodiazepine prescription in older patients dating back to
1991. One example is Beers’ criteria or list.8–10 This was orig-
inally developed for nursing home patients,8 but later modi-
fied to apply to all patients aged 65 years and older.9,10 It
identified 20 medications that should be completely avoided,
such as diazepam and chlordiazepoxide, and others where a
specified dosage and duration should not be exceeded (for
example, prescription of more than one month of a
short-acting benzodiazepine).8,9
In spite of this, epidemiologic data from Europe, Canada,
Japan, and Australia indicate that rates of benzodiazepine use
in the general population have remained steady at around
6%.11–15 Further, in spite of their greater susceptibility to
adverse effects, rates of long-term benzodiazepine use among
those aged 65 years and older are actually reported to be
higher than those of the general population (11% to 25%).16–18
International comparisons can provide information on the
influence of differing access to health care services and drug
insurance programs, formulary policies, and practitioner and
public education initiatives on drug use trends and conse-
quences.19–22 For example, access to benzodiazepines and
related drugs in Australia and the province of Nova Scotia dif-
fers significantly regarding both drug availability and reim-
bursement policies by public insurers, with only 4 agents
having equivalent status (Table 1). Nova Scotia has more
benzodiazepines and related drugs on the market than
Australia and more agents eligible for open coverage by pub-
lic insurance (14 and 5, respectively), but it is not known
whether this difference has any effect on prescribing and use.
The hypothesis to be tested was that use of benzodiazepines
and related compounds, in those aged 65 years and older and
those receiving social security payments, is similar in Nova
Scotia and Australia.
Methods
Data Sources
In Canada, we used administrative claims databases from the
Nova Scotia Pharmacare Program, which provided data on
benzodiazepines dispensed to those eligible for a subsidy
(seniors and social security beneficiaries, 80% of all Nova
Scotians aged 65 years and older), except for those already
with insurance, such as veterans and First Nations people.
These seniors pay a yearly premium (ranging from Can$215
in 2000 to Can$336 in 2003) and a copayment of 33% of the
total cost (to a maximum of Can$30) for each prescription.
Copayments are no longer required once the annual
copayment total of Can$350 has been reached. Community
service beneficiaries paid either no copayment (for those
with disabilities) or a Can$5 fee for each prescription.
The Australian Pharmaceutical Benefits Scheme has a simi-
lar administrative database,23 covering all Australian resi-
dents, with an equivalent population to the Nova Scotia
Pharmacare population (seniors and social security benefi-
ciaries, 75% of all Australians aged 65 years and older). The
copayments were about Can$3.50 for this type of beneficiary
(concession) in 2003. Concession beneficiaries were those
who receive social security payments (those with little or no
income), and includes individuals aged 65 years and older
and all women aged 62 years and older. Data on
benzodiazepines and related drugs dispensed to Australian
concession beneficiaries were obtained from the Australian
Pharmaceutical Benefits Scheme database. Similarities
between the 2 jurisdictions have allowed previous compari-
sons, for example, the use of statins.24,25
The study had approval from the Dalhousie University ethics
committee (2005–1052) in Halifax, Nova Scotia. As aggre-
gated de-identified data were used for Australia, ethics com-
mittee approval was not required.
Comparing the Quantity of Use
We recorded the use of each individual benzodiazepine and
related compounds, and total overall use each month, during
a 4-year period from 2000 to 2003. Prescriptions were con-
verted to DDDs.26,27 This standard measure represents the
average maintenance dose for each day of a drug when used
for its major indication. It overcomes difficulties in compar-
ing prescriptions of different price, pack size, duration, and
dose by relating all drug use to a standardized unit. We calcu-
lated the number of DDDs for each 1000 concession benefi-
ciaries each day (DDD/1000 beneficiaries/day) to compare
usage over time and place.28 Mean annual data points were
compared within and between each study site.
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Abbreviations used in this article
DDD defined daily dosage
DU90% drug usage 90%
Comparing the Quality of Use
DU90% measures the number of medications that form 90%
of prescribing for a particular drug class. Lower scores have
been proposed to provide an indicator of the quality of drug
prescribing.21 This is because a small range of medications for
any drug class allows physicians to gain a greater knowledge
of the available treatments.21 Prescribers, therefore, know
more about benefits, risks, and dosage regimes, and may be
less susceptible to industry promotion, if they only have to
become familiar with a smaller number of compounds.29 In
this study, we calculated the number and volume of drugs that
accounted for 90% of the total DDD/1000 beneficiaries/day
for benzodiazepines and related compounds. The drugs were
ranked from highest use to lowest use, as a percentage of the
total DDD/1000 beneficiaries/day. The drugs that constitute
90% of total use are referred to as DU90%.
Data Analysis
We performed linear regressions and Student t tests to com-
pare changes in the prescription of benzodiazepines and
related compounds over time and jurisdiction (GraphPad
Prism version 4.03, GraphPad Software, San Diego, Califor-
nia). Differences in the rate of increase were considered sta-
tistically significant at P < 0.05.
Results
The number of Pharmacare beneficiaries in Nova Scotia
ranged from a high of 169 000 in 2000 to a low of 155 000 in
2003 as Pharmacare became the insurer of last resort and
dropped coverage for those with other insurance. The num-
ber of concession beneficiaries in Australia ranged from
4 800 000 in 2000 to 5 000 000 in 2003. The 2 populations
were similar in terms of age and gender; 62% and 68% were
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Table 1 Summary of benzodiazepines and their availability and (or) public reimbursement in Nova Scotia
and Australia
Category, generic name
Marketed in
Canada
Reimbursed in
Nova Scotia
Marketed in
Australia
Reimbursed in
Australia
Benzodiazepines
Alprazolam Yes Yesa Yes Yes
Bromazepam Yes Yesa Yes Only for veterans
Chlordiazepoxide Yes Yes No No
Clobazam Yes Yesa Yes No
Clonazepam Yes Yes Yes Only for epilepsy
Clorazepate Yes Yesa No No
Diazepam Yes Yesa Yes Yes
Flunitrazepam No No Yes Only for veterans
Flurazepam Yes Nob No No
Lorazepam Yes Yesa Yes No
Midazolam Yes Yesc Yes No
Oxazepam Yes Yes Yes Yes
Nitrazepam Yes Nob Yes Yes
Temazepam Yes Yesa Yes Yes
Triazolam Yes Yesa Yes No
Aldehydes and derivatives
Chloral Hydrate Yes Yes Yes No
Benzodiazepine related drugs
Zaleplon Yes Nob No No
Zopiclone Yes Yesa Yes Only for veterans
Azaspirodecanedione derivative
Buspirone Yes Yesa Yes Only for veterans
aPartial subsidy
bIndividual authorization only
cSpecial criteria exists
aged 65 years or older in Nova Scotia and Australia, respec-
tively, and the proportion of women were 58% and 56%. The
prevalence of self-reported mental illness was 11.1% (95%CI,
9.5 to 12.8) in Nova Scotia,30 and 10.5% in Australia.15
The use of benzodiazepines increased at a steady but compa-
rable rate in both areas. However, the use of benzodiazepines
in Nova Scotia was more than double that of Australia from
2000 to 2003 (Figure 1). The observed increases over this
period were 15.5 (12.5%) and 9.2 (19%) DDD/1000 benefi-
ciaries/day in Nova Scotia and Australia, respectively. The
rate of increase did not differ between the jurisdictions (P =
0.12).
There was greater variety in benzodiazepine prescribing in
Nova Scotia as indicated by DU90% (Figure 2). Eight differ-
ent benzodiazepines made up 90% of the drug use in Nova
Scotia, compared with 4 in Australia. In 2003, lorazepam was
the most commonly used benzodiazepine in Nova Scotia
(25%), whereas diazepam was most commonly used in
Australia (33%). In total, 17 types of benzodiazepines and
related drugs were used in Nova Scotia in 2003 (Figure 3),
compared with 5 in Australia (Figure 4). The proportion of
long half-life agents used in Australia—47% (diazepam and
nitrazepam) was higher than in Nova Scotia—19% (diaze-
pam, clorazepate, flurazepam, and nitrazepam).
Discussion
This is the first study to directly compare 2 jurisdictions using
a standard methodology, and is particularly relevant at a time
when Canada consolidates its National Pharmaceutical Strat-
egy.31,32 We have shown that the use of benzodiazepines
increased at a steady but comparable rate in both Australia and
Nova Scotia. Of most concern to Canadian prescribers was
the finding that the use of benzodiazepines in Nova Scotia
was more than double that of Australia from 2000 to 2003,
even though the health systems in both countries have similar
characteristics.25,33 This may be relevant to physicians else-
where in Canada because the Atlantic region has, if anything,
significantly lower benzodiazepine use than the rest of the
nation.19 All this exists despite numerous initiatives to
improve rational prescription including the use of clinical
practice guidelines, electronic decision support tools, formu-
laries, copayments, therapeutic and generic substitution poli-
cies, and education of doctors and pharmacists.24,34–37 Of
particular concern is the continuing use of long-acting
benzodiazepines that are contraindicated in the elderly.8,9
Our results from Australia and Canada confirm findings from
the United States that benzodiazepines with longer half-lives
such as diazepam and nitrazepam are some of the most com-
mon compounds prescribed.38
Implications for Clinical Practice and Policy Change
Improving health status and reducing health care costs are
major themes of health care policies worldwide. To achieve
these goals, medicines need to be prescribed and used appro-
priately. For this reason, policies and guidelines for prescrib-
ing have been designed.32,39 Guidelines for benzodiazepines
and related compounds, including the Beers’ list,8–10 recom-
mend that benzodiazepine use should be limited in the elderly
to low dosages of a short- or medium-acting agent for no
more than one month.8–10,40 However, the results of our study
suggest these are not being implemented. Indeed, benzodiaz-
epine use is increasing in this vulnerable population, and use
in Nova Scotia is more than twice the use in Australia.
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Figure 1 Overall use of all benzodiazepines among Pharmacare Program beneficiaries in Nova
Scotia, and beneficiaries in Australia, from 2000 to 2003
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Figure 3 Proportion of each benzodiazepine and related compounds used by Nova Scotia
Pharmacare Program beneficiaries in 2003, using DDDs
Figure 2 DU90% for benzodiazepines and use of all benzodiazepines among
Pharmacare Program beneficiaries in Nova Scotia, and beneficiaries in
Australia, from 2000 to 2003
Prescriber-related factors contributing to this increase in use
could include knowledge, confusion over differing
psychotropic guidelines, difficulties in discontinuing an inap-
propriate medication started by a previous physician, multiple
prescribers and pharmacies involved in the care of a patient,
negative perceptions regarding aging, and cost issues.41
Patients may contribute to the problem by demanding an inap-
propriate medication. Finally, the inclusion or exclusion of
specific medications in hospitals, health care plans, or provin-
cial formularies may exacerbate the problem through the
inclusion of excessive number of compounds for a given med-
ication class.38 Successful strategies to foster appropriate pre-
scribing need to address all of these factors through
educational and administrative approaches.38
For physicians, these strategies include educational
approaches such as one-on-one sessions and academic detail-
ing. Education could be complemented by the use of personal
formularies, where prescribers have a short personal list of
drugs that are effective for, and tolerated by, the patients they
treat.29,38 This technique can be easily taught to medical stu-
dents through textbooks, national formularies, and guide-
lines.42 Evidence also suggests that most seniors can be
gradually tapered off benzodiazepines, while avoiding nega-
tive effects of withdrawal.43 Media campaigns and letters to
patients can encourage them to gradually discontinue their
benzodiazepine in partnership with their family physician.44
Initiatives such as these can achieve 20% to 30% reductions in
long-term benzodiazepine use.45–48
Our data also suggest an association between the number and
range of benzodiazepines prescribed. Nova Scotia reimburses
17 benzodiazepines, while Australia only reimburses 5.
Administrative approaches could therefore include limits on
the range of medications available for any particular drug
class, allowing physicians to gain greater knowledge of the
medications they prescribe.21
Limitations of This Study
This study used administrative databases designed for phar-
macist payment rather than for drug usage studies, which lack
clinical data related to patient characteristics and reason for
use. Therefore these data need to be interpreted with care.
The databases do not allow individual tracking of patients,
therefore coprescribing with other medication, or doubling or
tripling the dose on benzodiazepine use cannot be
quantitated. The data indicated dispensed medication (rather
than actual prescribed medicine or actual taken medicine),
and so do not take into account primary noncompliance
(medication prescribed but the prescription not filled) or non-
compliance by the patient (medication prescribed and dis-
pensed but not actually taken by the patient). The data are
only available for subsidized medicines, dispensed to indi-
viduals aged 65 years and older, not otherwise insured, or
receiving social benefits (and therefore entitled to subsidized
medicines) in Nova Scotia, or dispensed to those receiving an
old-age pension, or receiving social security benefits in
Australia. The groups are essentially similar, in particular the
proportion aged 65 years and older, but there may be some
minor differences in the populations. We were only able to
compare the Australian data with data from one Canadian
province; we therefore do not know how generalizable the
findings would be to other parts of Canada. The DDD meth-
odology may not reflect the actual dosage taken, especially if
the medication was not used regularly. The knowledge,
skills, and attitudes about benzodiazepine prescribing among
physicians and the beliefs and values among patients may
also be different in Nova Scotia and Australia.
Conclusion
This study found major differences in the type and rate of
benzodiazepine prescribing in Nova Scotia and Australia.
Benzodiazepine use increased in both Nova Scotia and
Australia during the period, with benzodiazepine usage being
twice as high in Nova Scotia than Australia. Of particular
concern was the continuing use of long-act ing
benzodiazepines, which are contraindicated in this age
group.8,9 This study has suggested that the high use of
benzodiazepines in Nova Scotia may be due to Nova Scotia
having 12 more benzodiazepines (and related compounds)
available than Australia. It may be possible to achieve a
decrease in use by promoting the use of guidelines and
enhancing awareness of the level and burden of benzodiaz-
epine use, especially in those aged 65 years and older. The
effects of different formulary policies of drug insurance pro-
grams, funding, beliefs and attitudes of patients and prescrib-
ers, and education therefore merit further investigation.
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Original Research
Résumé : Une comparaison de l’utilisation de benzodiazépines et de médicaments
connexes en Nouvelle-Écosse et en Australie
Objectif : Les benzodiazépines peuvent poser un problème si elles sont utilisées sur de longues
périodes, ou par des populations à risque, comme les personnes âgées. Nous avons comparé
l’utilisation de benzodiazépines et de médicaments sur ordonnance connexes en Nouvelle-Écosse
et en Australie.
Méthodes : Le programme d’assurance-médicaments de la Nouvelle-Écosse et celui d’Australie
(le Pharmaceutical Benefits Scheme) ont servi à obtenir les données sur les ordonnances dans des
populations comparables pour toutes les benzodiazépines et tous les composés connexes
subventionnés par l’État. L’utilisation a été comparée de 2000 à 2003, à l’aide des codes de
classification anatomique thérapeutique chimique et du système de doses thérapeutiques
quotidiennes (DTQ) de l’Organisation mondiale de la santé. Nous avons aussi déterminé les
différences entre les types de benzodiazépines prescrites.
Résultats : L’utilisation de benzodiazépines a augmenté à un rythme régulier mais comparable dans
les deux régions. Cependant, l’utilisation de benzodiazépines en Nouvelle-Écosse était plus que le
double de celle de l’Australie en 2000 (123 et 48 DTQ/1000 bénéficiaires chaque jour,
respectivement) jusqu’en 2003 (138 et 57 DTQ/1000 bénéficiaires chaque jour, respectivement).
Huit différentes benzodiazépines constituaient 90 % de l’utilisation de médicaments en
Nouvelle-Écosse, contrairement à seulement 4 différentes benzodiazépines en Australie.
Conclusions : De grandes différences existent entre le type et le taux des prescriptions de
benzodiazépines en Nouvelle-Écosse et en Australie, la Nouvelle-Écosse déclarant plus que le
double de l’utilisation. L’utilisation de benzodiazépines augmente dans les deux territoires. Les
résultats canadiens sont particulièrement préoccupants car il a été signalé que l’utilisation de
benzodiazépines était moindre dans les provinces atlantiques que dans les autres provinces. Les
variations entre les 2 territoires peuvent être attribuables à des facteurs comme l’offre réduite de
benzodiazépines en Australie, les différences chez les prescripteurs, les attitudes et le comportement
des patients, ou les différentes initiatives influençant l’utilisation de benzodiazépines.
